Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies
Open accessThe DOI matches its Crossref record; 156 of the 156 references it cites were found in a registry or an index; 37 of the 185 sources its claims cite were checked for support.
Abstract
Cetuximab and panitumumab are monoclonal antibodies (mAbs) against epidermal growth factor receptor (EGFR) that are effective agents for metastatic colorectal cancer (mCRC). Cetuximab can prolong survival by 8.2 months in RAS wild-type (WT) mCRC patients. Unfortunately, resistance to targeted therapy impairs clinical use and efficiency. The mechanisms of resistance refer to intrinsic and extrinsic alterations of tumours. Multiple therapeutic strategies have been investigated extensively to overcome resistance to anti-EGFR mAbs. The intrinsic mechanisms include EGFR ligand overexpression, EGFR alteration,RAS/RAF/PI3K gene mutations, ERBB2/MET/IGF-1R activation, metabolic remodelling, microsatellite instability and autophagy. For intrinsic mechanisms, therapies mainly cover the following: new EGFR-targeted inhibitors, a combination of multitargeted inhibitors, and metabolic regulators. In addition, new cytotoxic drugs and small molecule compounds increase the efficiency of cetuximab. Extrinsic alterations mainly disrupt the tumour microenvironment, specifically immune cells, cancer-associated fibroblasts (CAFs) and angiogenesis. The directions include the modification or activation of immune cells and suppression of CAFs and anti-VEGFR agents. In this review, we focus on the mechanisms of resistance to anti-EGFR monoclonal antibodies (anti-EGFR mAbs) and discuss diverse approaches to reverse resistance to this therapy in hopes of identifying more mCRC treatment possibilities.
Overview
CoChat Summary
TL;DR
This review summarizes intrinsic and extrinsic mechanisms of resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer and discusses preclinical and clinical strategies to reverse that resistance. It emphasizes that resistance is driven by genetic alterations, compensatory signaling, metabolic remodeling, immune microenvironment changes, CAFs, and angiogenesis, with combination and multitargeted approaches showing the most promise.
Key findings
- Anti-EGFR mAbs benefit only a subset of mCRC patients: cetuximab plus FOLFIRI reduced progression risk by 15% and increased OS by 8.2 months in KRAS WT mCRC versus FOLFIRI alone, but clinical benefit in responders lasts only 8–10 months, and approximately 80% of responders develop resistance.
- Intrinsic resistance mechanisms include EGFR ligand overexpression, EGFR extracellular domain mutations (e.g., G465R, G465E, S468R, S492R), RAS/RAF/PI3K pathway mutations, ERBB2/MET/IGF-1R activation, metabolic remodeling, microsatellite instability, autophagy, CSCs, and EMT.
- Reversal strategies include new anti-EGFR antibodies (necitumumab, Sym004, GC1118, MM-151), multitargeted inhibitors, metabolic regulators, immune therapies, CAF suppression, and antiangiogenic agents. Notable reported results include encorafenib + binimetinib + cetuximab in BRAF V600E mCRC (ORR 26% vs 2%; mOS 9.0 vs 5.4 months), capmatinib + gefitinib in MET-amplified disease (ORR 47%), and tivantinib + cetuximab (ORR 9.8%, mPFS 2.6 months, mOS 9.2 months).
- Extrinsic resistance involves impaired ADCC, dysfunctional NK/T cells, CAF-secreted growth factors, and angiogenesis; avelumab + cetuximab in RAS WT acquired resistance gave mPFS 3.6 months and mOS 11.6 months, while regorafenib + cetuximab produced partial response in 1/17 and stable disease in 7/17 patients.
Methods
- Narrative review of published literature on mechanisms of resistance to anti-EGFR mAbs in mCRC and strategies to reverse resistance.
- Synthesizes preclinical and clinical evidence, including two summary tables: Table 1 for clinical trials and Table 2 for preclinical studies.
- No primary experimental data, systematic search strategy, or meta-analysis is described.
Limitations
- The paper does not state formal limitations.
- Evident from the text: as a review, it provides no new primary data, and conclusions depend on cited studies that include small, early-phase, case-report, and preclinical evidence.
- Evident from the text: several strategies show conflicting or negative results (e.g., vemurafenib studies, PX-866 plus cetuximab, selumetinib plus cetuximab, dalotuzumab/IMC-A12), and the paper notes that more clinical studies are needed for MEK inhibitors, new anti-EGFR mAbs, and cytotoxic agents before clinical application.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
25 Valid · 2 Not valid · 105 Not checked · 21 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“EGFR somatic sequence changes, including G465R, G465E, S468R and S492R, located at the extracellular domains (ECDs) of the EGFR-mAb interaction interface, confer resistance to cetuximab and panitumumab by preventing mAb binding [10, 67, 68].”
§ Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies > Intrinsic mechanisms of resistance to targeted therapy and related strategies > EGFR ligands and EGFR
What the sources say
- Partly supportedcites [10] Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature. 2015;526(7572):263–7. https://doi.org/10.1038/nature14969. sourceExperimental — accuracy not yet measured
The paper’s discussion of EGFR ectodomain alterations and Extended Data Figure 2 identify G465R and G465E at the antibody-binding interface and link them to cetuximab resistance; it also reports poor panitumumab sensitivity for G465E tumorgrafts. But the paper says S492R-altered tumors remain sensitive to panitumumab, does not identify S468R in the passages retrieved, and describes impaired binding as a structural inference rather than demonstrating prevention of binding for all four changes. No page numbers are provided in our copy. (LLM, conf=0.90)
- Partly supportedcites [67] Van Emburgh BO, Arena S, Siravegna G, Lazzari L, Crisafulli G, Corti G, et al. Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nat Commun. 2016;7:13665. https://doi.org/10.1038/ncomms13665. sourceExperimental — accuracy not yet measured
The introductory passage says EGFR extracellular-domain variants impair anti-EGFR antibody binding, and the Discussion identifies mutations in the antibody-binding site as a resistance mechanism. The Results identify S492R in cells exposed to cetuximab. Our copy does not identify G465R, G465E, or S468R, or establish that each listed change prevents binding of both cetuximab and panitumumab. (LLM, conf=0.85)
- Disputedcites [68] Price T, Ang A, Boedigheimer M, Kim TW, Li J, Cascinu S, et al. Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy. Cancer Biol Ther. 2020;21(10):891–8. https://doi.org/10.1080/15384047.2020.1798695. sourceExperimental — accuracy not yet measured
The Results (In vitro receptor binding and activity; page unavailable) show that panitumumab, but not cetuximab, bound to and inhibited S492R mutant EGFR. Thus the claim that S492R prevents binding and confers resistance to both antibodies contradicts this paper. The Discussion mentions G465R resistance to cetuximab, but the retrieved passages do not establish the claimed effects of G465E or S468R. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The hotspot BRAF V600E mutation at codon 600 of exon 15 increases the activity of BRAF kinase by 130- to 700-fold [26, 93–95].”
§ Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies > Intrinsic mechanisms of resistance to targeted therapy and related strategies > Compensatory feedback loop signalling
What the sources say
- Not checked yetcites [26] Shinozaki E, Yoshino T, Yamazaki K, Muro K, Yamaguchi K, Nishina T, et al. Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the biomarker research for anti-EGFR monoclonal antibodies by comprehensive Cancer genomics (BREAC) study. Br J Cancer. 2017;117(10):1450–8. https://doi.org/10.1038/bjc.2017.308. source
- Could not verifycites [93] Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun. 2013;4:2185. https://doi.org/10.1038/ncomms3185. sourceExperimental — accuracy not yet measured
The Results section reports the presence of BRAF V600E in melanomas, but does not discuss its effect on BRAF kinase activity. Searches for exon 15, codon 600, and a 130- to 700-fold activity increase found no passage addressing those parts of the claim; page numbers were unavailable in our copy. (LLM, conf=0.76)
- Not checked yetcites [94] Pakneshan S, Salajegheh A, Smith RA, Lam AK. Clinicopathological relevance of BRAF mutations in human cancer. Pathology. 2013;45(4):346–56. https://doi.org/10.1097/PAT.0b013e328360b61d. source
- Disputedcites [95] Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54. https://doi.org/10.1038/nature00766. sourceExperimental — accuracy not yet measured
The kinase assay in “letters to nature” (p. 3) reports that V599E BRAF had about 10.7-fold the basal kinase activity of wild-type BRAF, not 130- to 700-fold. The same page reports a 70- to 138-fold increase in cell transformation, which is a different measure from kinase activity. Our copy calls the mutation V599E. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Mutations in exons 2, 3 and 4 of KRAS and exons 2, 3, and 4 of NRAS are powerful predictors for cetuximab and panitumumab response in mCRC [81, 82].”
§ Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies > Intrinsic mechanisms of resistance to targeted therapy and related strategies > Compensatory feedback loop signalling
What the sources say
- Partly supportedcites [81] Bokemeyer C, Köhne CH, Ciardiello F, Lenz HJ, Heinemann V, Klinkhardt U, et al. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. Eur J Cancer. 2015;51(10):1243–52. https://doi.org/10.1016/j.ejca.2015.04.007. sourceExperimental — accuracy not yet measured
The Introduction reports poorer outcomes with KRAS exon 2 mutations for both cetuximab and panitumumab and cites evidence linking other RAS mutations to poorer panitumumab outcomes. But this paper directly studies cetuximab, not panitumumab, and its Results say the small subgroup with other RAS mutations did not permit a formal assessment of predictive effects; calling mutations across all the listed exons “powerful predictors” overstates its findings. Page numbers are not available in our copy. (LLM, conf=0.88)
- Partly supportedcites [82] Blons H, Emile JF, Le Malicot K, Julié C, Zaanan A, Tabernero J, et al. Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. Ann Oncol. 2014;25(12):2378–85. https://doi.org/10.1093/annonc/mdu464. sourceExperimental — accuracy not yet measured
The Introduction (p. 2) says KRAS status predicts resistance to EGFR inhibitors in metastatic colorectal cancer. It does not establish the claimed predictive value for KRAS and NRAS mutations across exons 2, 3, and 4, or specifically address response to both cetuximab and panitumumab; the Discussion (p. 5) describes testing KRAS exon 2 and BRAF mutations for prognosis in stage III disease. (LLM, conf=0.88)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Gene mutations downstream of the EGFR signalling pathway, including RAS/RAF/MEK and PI3K/AKT/mTOR, significantly contribute to drug resistance [9–11].”
§ Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies > Background
What the sources say
- Not checked yetcites [9] Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757–65. https://doi.org/10.1056/NEJMoa0804385. source
- Supportedcites [10] Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature. 2015;526(7572):263–7. https://doi.org/10.1038/nature14969. source
The Abstract (Results passage) states that in KRAS wild-type CRC tumorgrafts, alterations in all genes known to be involved in EGFR therapeutic resistance — NRAS, BRAF V600E, MET, ERBB2, plus PIK3CA exon 20 and PTEN truncating/deletion alterations — were detected in cetuximab-resistant tumors, and that 'the enrichment of mutations in these pathways in the resistant tumorgrafts was statistically significant (p<0.001)' and 'alterations in any of these members may be sufficient to render cells insensitive to EGFR inhibition'. Extended Data Fig. 1 is titled 'EGFR signaling pathway genes involved in cetuximab resistance or sensitivity' and depicts members of the RAS and PI3K pathways, while Extended Data Fig. 4 shows ectopic expression of resistance-associated mutations (EGFR G465E, MAP2K1 K57N) inducing cetuximab resistance — supporting a causal contribution of RAS/RAF/MEK and PI3K pathway mutations to anti-EGFR antibody resistance. The pathway naming 'PI3K/AKT/mTOR' is a generic label; our copy documents PIK3CA/PTEN (and AKT signalling via IRS2) rather than MTOR mutations, which does not weaken the attributed point. (LLM, conf=0.85)
- Not checked yetcites [11] De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753–62. https://doi.org/10.1016/S1470-2045(10)70130-3. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Progression-free survival (PFS) and OS of patients taking necitumumab plus mFOLFOX6 were comparable to those of the cetuximab and FOLFOX regimens [21].”
§ Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies > Intrinsic mechanisms of resistance to targeted therapy and related strategies > EGFR ligands and EGFR
What the sources say
- Supportedcites [21] Elez E, Hendlisz A, Delaunoit T, Sastre J, Cervantes A, Varea R, et al. Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer. Br J Cancer. 2016;114(4):372–80. https://doi.org/10.1038/bjc.2015.480. source
The Discussion explicitly states that OS and PFS with necitumumab plus mFOLFOX6 were comparable with those reported in previous studies of cetuximab combined with FOLFOX regimens. This is a cross-trial comparison, not a head-to-head finding. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
106 more claims · 17 with their cited sources checked
Create a free account to see all 153 claims and to verify the 148 references still open.
- Probably not a substantial claim. 6
- It may state two separate claims as one. 38
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Progressive disease following anti-EGFR therapy may result from acquired resistance [45,46], which may result from any one of several causes [47].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies > Intrinsic mechanisms of resistance to targeted therapy and related strategies
“| Immunity therapy | CAFs | BLU9931 | Cell | Unselected | BLU9931 + cetuximab VS cetuximab | Sensitive VS insensitive | [58] |”
§ Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies > Extrinsic mechanisms of resistance to targeted therapy and related strategies > CAFs and inhibitors
“The combination of BLU9931,an FGFR4 inhibitor, with cetuximab presented profound antitumour activity compared to cetuximab alone [57]. Regorafenib, a multikinase inhibitor targeting FGFR, VEGF and PDGFR-β, was found to overcome cetuximab resistance in GEO-CR and SW48-CR cells in vitro and in vivo [58].”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies > Intrinsic mechanisms of resistance to targeted therapy and related strategies
“| MET inhibitors | MET | Tivantinib | Phase II | mCRC | KRAS mutation | Tivantinib + cetuximab | ORR: 9.8%, mPFS: 2.6m,mOS:9.2m | [33] |”
§ Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies > References
“33. Rimassa L Bozzarelli S Pietrantonio F Cordio S Lonardi S Toppo L Zaniboni A Bordonaro R Di Bartolomeo M Tomasello G Phase II study of Tivantinib and Cetuximab in patients with KRAS wild-type metastatic colorectal Cancer with acquired resistance to EGFR inhibitors and emergence of MET overexpression:”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies > Intrinsic mechanisms of resistance to targeted therapy and related strategies
“| MET inhibitors | MET | Capmatinib | Phase II | mCRC | MET amplification | Capmatinib + gefitinib | ORR: 47% | [34] |”
§ Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies > References
“34. Wu YL Zhang L Kim DW Liu X Lee DH Yang JC Ahn MJ Vansteenkiste JF Su WC Felip E Phase Ib/II study of Capmatinib (INC280) plus Gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung Cancer”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies > Intrinsic mechanisms of resistance to targeted therapy and related strategies
“| New anti-EGFR mAbs | EGFR ECD | Sym004 | Phase I | mCRC | KRAS WT | Sym004 or investigator’s choice | mOS: 12.8m VS 7.3m | [22] |”
§ Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies > Intrinsic mechanisms of resistance to targeted therapy and related strategies > EGFR ligands and EGFR
“A multicentre, phase 2 clinical trial further confirmed that Sym004 improved the OS of anti-EGFR-refractory mCRC by 5.5 months [22].”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies > Intrinsic mechanisms of resistance to targeted therapy and related strategies
“| IGF-1R inhibitors | IGF-1R | IMC-A12 | Phase II | mCRC | Unselected | IMC-A12 + cetuximab VS IMC-A12 | Non response | [36] |”
§ Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies > References
“36. Sclafani F Kim TY Cunningham D Kim TW Tabernero J Schmoll HJ Roh JK Kim SY Park YS Guren TK A randomized phase II/III study of Dalotuzumab in combination with Cetuximab and irinotecan”
2 more findings
Create a free account to see every finding of this check.
Citations
Cites
1 retracted
Targeting CD137 enhances the efficacy of cetuximab
Kohrt, H. E., Colevas, A. D., Houot, R., Weiskopf, K., Goldstein, M. J., Lund, P., Mueller, A., Sagiv-Barfi, I., Marabelle, A., Lira, R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73014 · Cited by 160
RetractedBray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Microsatellite Instability in Colorectal Cancer
Boland, C. R., & Goel, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.064 · Cited by 2,456
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882
Cited by
Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
Kumar, A., Gautam, V., Sandhu, A., Rawat, K., Sharma, A., & Saha, L. (2023) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v15.i4.495 · Cited by 272
Menyhárt, O., Fekete, J. T., & Győrffy, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158441 · Cited by 134
“Nevertheless, despite combination therapies, more than half of patients relapse to multidrug-resistant disease [13], and the mortality rate remains relatively high among CRC patients [3].”
BackgroundFerreira, A. I., Pereira, F. D. S., Reis, C. A., Oliveira, M. J., Sousa, M. J., & Preto, A. (2022) · Cells · doi:10.3390/cells11142183 · Cited by 123
Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system
Sun, X., Zhao, P., Lin, J., Chen, K., & Shen, J. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.16 · Cited by 96
“Among them, the activating mutations of oncogenes such as EGFR, RAS, RAF, and PI3K are the key driving factors for many cancers([86-89]).”
BackgroundCracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers
Du, Y.-F., Karatekin, F., Wang, W. K., Hong, W., & Gandhi, T. K. B. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100076 · Cited by 114
Metadata
- Authors
- Zhou, J., Ji, Q., & Li, Q.
- Affiliations
- Shanghai University of Traditional Chinese Medicine (CN)
- Corresponding author
- Ji, Qing
- Li, Qi
- Venue
- Journal of Experimental & Clinical Cancer Research
- Published
- 2021-10-18
- Volume
- 40
- Issue
- 1
- Pages
- 328-328
- ISSN
- 0392-9078 (ISSN-L)
- 1756-9966
- PMC
- PMC8522158
- OpenAlex
- W3207379781
- Cited by
- 246
- References
- 156
- Citations by year
- 2026: 53 · 2025: 71 · 2024: 60 · 2023: 38 · 2022: 24
- FWCI
- 3.70
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of Experimental & Clinical Cancer Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- national natural science foundation of china (81830120, 82074225)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- metastatic colorectal cancer, anti-EGFR monoclonal antibody, cetuximab, panitumumab, anti-EGFR therapy resistance, metabolic remodeling, microsatellite instability, autophagy, tumor microenvironment, cancer-associated fibroblasts, angiogenesis, immune cells, combination therapy
- MeSH terms
- Clinical Decision-Making, Drug Development, Animals, Antineoplastic Agents, Clinical Trials as Topic, Energy Metabolism, Gene Amplification, Humans, Ligands, Mutation, Neovascularization, Pathologic, Protein Binding, Colorectal Neoplasms, Signal Transduction, Treatment Outcome, Drug Resistance, Neoplasm, Disease Management, Protein Kinase Inhibitors, Microsatellite Instability, Molecular Targeted Therapy, Tumor Microenvironment, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies. https://app.cochat.ai/papers/10.1186/s13046-021-02130-2
- The paper
- Zhou, J., Ji, Q., & Li, Q. (2021). Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-021-02130-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.